News and Press Releases
Global oncology trial investigator sites increase by half in five years, finds new Phesi analysis
China flagged as significant contributor to growth, but poor investigator selection is causing trial failures 23 May 2024 -- Massachusetts, US -- Phesi, a leading clinical development analytics company, has...
Category: Biotechnology, Clinical Trials
Posted: May 22, 2024
Sartorius to Advance Drug Discovery and Manufacturing with AI in Collaboration with NVIDIA
Exploring advanced technologies to help bring novel therapies to patients faster Sartorius to leverage NVIDIA solutions used in live-cell imaging platforms in drug discovery, predictive design of manufacturing processes and...
Category: Biotechnology, Drug Discovery
Posted: May 16, 2024
Sartorius Corporation, Otto-Brenner-Straße 20, 37079 Goettingen, Germany
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
Non-Small Cell Lung Cancer (NSCLC) Development Program Data to be Presented, Including the phase 3 EVOKE-01 Study Updated Results from phase 2 EDGE-Gastric Study of Fc-Silent Anti-TIGIT Domvanalimab Plus Anti-PD-1...
Category: Clinical Trials, Drug Discovery
Posted: May 7, 2024
Owlstone Medical Secures $6.5m to Support Development of Breath-based Diagnostics for Infectious Disease
$5m equity investment and initial $1.5m grant funding committed by the Bill & Melinda Gates Foundation for development of breath-based diagnostic solutions to improve outcomes in the developing world Funding...
Category: Biotechnology, Other
Posted: April 25, 2024
Owlstone Ltd, 127 Cambridge Science Park, Milton Road, Cambridge, CB4 0GD, UK
How the Birmingham Drug Discovery Hub created an investment-ready ‘drug library’
18 April 2024 -- Birmingham, UK -- A novel approach to drug discovery is enabling University of Birmingham, UK, researchers to overcome the ‘valley of death’, where projects fail due...
Category: Drug Discovery
Posted: April 18, 2024
Kite to Present Comparison of Outcomes of Tecartus (brexucabtagene autoleucel) from the Pivotal ZUMA-2 Trial Versus the EBMT Registry of alloSCT Patients in Mantle Cell Lymphoma (MCL) at 50th EBMT 2024
Additional analysis demonstrates cost-effectiveness of axicabtagene ciloleucel versus standard of care as second-line therapy In patients With large B-cell lymphoma In Italy 9 April 2024 -- Stockley Park, UK --...
Category: Biotechnology, Clinical Trials
Posted: April 12, 2024
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study
NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: April 10, 2024
X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy
2 April 2024 -- Massachusetts, US -- X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr Erin Davis as chief technology officer....
Category: Drug Discovery
Posted: April 2, 2024
Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software
2 April 2024 -- Birmingham, UK -- Genetic testing company, Nonacus, has launched GALEAS Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumours, allowing clinicians...
Category: Biotechnology
Posted: April 2, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham B32 1AF, United Kingdom
Eisbach and Cancer Focus Fund Announce $4.5m Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumours
Eisbach is enabling the potential of synthetic lethality by developing novel compounds to exploit molecular vulnerabilities uniquely present in many hard-to-treat cancers 21 March 2024 -- Martinsried, Germany and Texas, US...
Category: Biotechnology, Pharmaceutical
Posted: March 21, 2024
Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery
Expansion to SemaCyte Microcarrier platform enables optical barcoding and pooling of adherent cells to augment drug discovery high-content imaging and other screening processes Access available through Semarion’s Early Adopter Programme....
Category: Drug Discovery
Posted: March 20, 2024
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics 11 March 2024 -- Dundee, UK --...
Category: Drug Discovery
Posted: March 11, 2024
University Incubator Dundee Technopole James Lindsay Place Dundee DD1 5JJ Scotland, UK
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Aston University and University of Warwick team wins £1.8m for research to aid drug discovery and sustainable chemical production
The team will engineer cells to make membrane proteins efficiently The proteins will be used for drug discovery and screening, and as catalysts in sustainable chemical production The £1.8m Engineering...
Category: Drug Discovery
Posted: February 12, 2024
Informed Genomics Limited comments on launch of national BRCA gene testing programme to identify cancer risk early
7 February 2024 -- Birmingham, UK -- NHS England have launched a genetic testing programme targeting tens of thousands of people with Jewish ancestry who are more likely to carry...
Category: Biotechnology
Posted: February 7, 2024
Unit 5, Quinton Business Park, 11 Ridgeway, Quinton, Birmingham, B32 1AF
